These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37146162)

  • 1. Chemometrics in Protein Formulation: Stability Governed by Repulsion and Protein Unfolding.
    Kulakova A; Augustijn D; El Bialy I; Gentiluomo L; Greco ML; Hervø-Hansen S; Indrakumar S; Mahapatra S; Martinez Morales M; Pohl C; Polimeni M; Roche A; Svilenov HL; Tosstorff A; Zalar M; Curtis R; Derrick JP; Frieß W; Golovanov AP; Lund M; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Roessner D; Streicher WW; van der Walle CF; Warwicker J; Uddin S; Winter G; Bukrinski JT; Rinnan Å; Harris P
    Mol Pharm; 2023 Jun; 20(6):2951-2965. PubMed ID: 37146162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.
    Svilenov H; Winter G
    Eur J Pharm Biopharm; 2019 Apr; 137():131-139. PubMed ID: 30818009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of arginine glutamate on the stability of monoclonal antibodies in solution.
    Kheddo P; Tracka M; Armer J; Dearman RJ; Uddin S; van der Walle CF; Golovanov AP
    Int J Pharm; 2014 Oct; 473(1-2):126-33. PubMed ID: 24992318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
    Goldberg DS; Bishop SM; Shah AU; Sathish HA
    J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
    Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
    Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse Proteolysis: An Orthogonal Tool for Protein Formulation Screening.
    Iyer LK; Phanse R; Xu M; Lan W; Krause ME; Bolgar M; Hart S
    J Pharm Sci; 2019 Feb; 108(2):842-850. PubMed ID: 30257193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orthogonal Techniques to Study the Effect of pH, Sucrose, and Arginine Salts on Monoclonal Antibody Physical Stability and Aggregation During Long-Term Storage.
    Svilenov HL; Kulakova A; Zalar M; Golovanov AP; Harris P; Winter G
    J Pharm Sci; 2020 Jan; 109(1):584-594. PubMed ID: 31689429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
    Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
    J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of highly concentrated antibody solution - A toolbox for the description of protein long-term solution stability.
    Schermeyer MT; Wöll AK; Kokke B; Eppink M; Hubbuch J
    MAbs; 2017 Oct; 9(7):1169-1185. PubMed ID: 28617076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.
    Thiagarajan G; Semple A; James JK; Cheung JK; Shameem M
    MAbs; 2016; 8(6):1088-97. PubMed ID: 27210456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermodynamic Unfolding and Aggregation Fingerprints of Monoclonal Antibodies Using Thermal Profiling.
    Melien R; Garidel P; Hinderberger D; Blech M
    Pharm Res; 2020 Apr; 37(4):78. PubMed ID: 32236701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations.
    He F; Woods CE; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Dec; 100(12):5126-41. PubMed ID: 21789772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulations That Suppress Aggregation During Long-Term Storage of a Bispecific Antibody are Characterized by High Refoldability and Colloidal Stability.
    Svilenov HL; Winter G
    J Pharm Sci; 2020 Jun; 109(6):2048-2058. PubMed ID: 32194093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
    Brummitt RK; Nesta DP; Roberts CJ
    J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension to Predict Surfactant Requirements for Biological Formulations.
    Vargo KB; Stahl P; Hwang B; Hwang E; Giordano D; Randolph P; Celentano C; Hepler R; Amin K
    Mol Pharm; 2021 Jan; 18(1):148-157. PubMed ID: 33253579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.